Informations générales (source: ClinicalTrials.gov)

NCT03930953 Active, sans recrutement
A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Interventional
  • Lymphomes
  • Lymphome malin non hodgkinien
  • Récidive
Phase 1/Phase 2
Celgene (Voir sur ClinicalTrials)
mai 2019
février 2028
02 mars 2026
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Vincent RIBRAG En recrutement IDF 17/05/2024 13:48:09  Contacter

Critères

Tous
Inclusion Criteria

- History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease.

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

Exclusion Criteria

- Life expectancy ≤ 2 months.

- Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5
half-lives or 4 weeks prior to starting CC-99282, whichever is shorter.

- Is on chronic systemic immunosuppressive therapy or corticosteroids or has
clinically significant graft-versus-host disease (GVHD).

- Impaired cardiac function or clinically significant cardiac disease.

- Other protocol-defined inclusion/exclusion criteria apply.